Tags

Type your tag names separated by a space and hit enter

Medical treatment of levodopa-induced dyskinesias.
Ann Neurol. 2000 Apr; 47(4 Suppl 1):S179-88.AN

Abstract

Clinicians can presently choose from three main pharmacological strategies to medically treat levodopa-induced dyskinesias (LIDs): prevent the occurrence of the priming phenomenon, which generates dyskinesias; reverse, once primed, the changes that occurred in the basal ganglia to induce dyskinesias; or avoid the expression of dyskinesias in an already primed brain. To prevent, at least partly, priming for dyskinesias can be attempted by delaying the need for levodopa, and/or reducing the cumulative dose of levodopa, using, for example, dopamine D2 agonists at the early stages of treatment. The question of reversibility of dyskinesia priming remains a matter of controversy. Any improvement gained from a drug holiday can be short lived, and the re-introduction of levodopa can re-prime the patient. Reducing the dose of levodopa and using other drugs as an adjunct has proved inconsistent. High-frequency deep brain stimulation of the subthalamic nuclei and mesencephalic embryonic cell grafts have shown potential in small numbers of patients. To avoid the expression of dyskinesias in already primed patients, agents that act on either the dopamine or nondopaminergic receptors have been used. For example, amantadine, given as an adjuvant to levodopa, has been shown to improve dyskinesias, but larger, controlled studies are required.

Authors

No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10762146

Citation

Rascol, O. "Medical Treatment of Levodopa-induced Dyskinesias." Annals of Neurology, vol. 47, no. 4 Suppl 1, 2000, pp. S179-88.
Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol. 2000;47(4 Suppl 1):S179-88.
Rascol, O. (2000). Medical treatment of levodopa-induced dyskinesias. Annals of Neurology, 47(4 Suppl 1), S179-88.
Rascol O. Medical Treatment of Levodopa-induced Dyskinesias. Ann Neurol. 2000;47(4 Suppl 1):S179-88. PubMed PMID: 10762146.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medical treatment of levodopa-induced dyskinesias. A1 - Rascol,O, PY - 2000/4/13/pubmed PY - 2000/4/29/medline PY - 2000/4/13/entrez SP - S179 EP - 88 JF - Annals of neurology JO - Ann Neurol VL - 47 IS - 4 Suppl 1 N2 - Clinicians can presently choose from three main pharmacological strategies to medically treat levodopa-induced dyskinesias (LIDs): prevent the occurrence of the priming phenomenon, which generates dyskinesias; reverse, once primed, the changes that occurred in the basal ganglia to induce dyskinesias; or avoid the expression of dyskinesias in an already primed brain. To prevent, at least partly, priming for dyskinesias can be attempted by delaying the need for levodopa, and/or reducing the cumulative dose of levodopa, using, for example, dopamine D2 agonists at the early stages of treatment. The question of reversibility of dyskinesia priming remains a matter of controversy. Any improvement gained from a drug holiday can be short lived, and the re-introduction of levodopa can re-prime the patient. Reducing the dose of levodopa and using other drugs as an adjunct has proved inconsistent. High-frequency deep brain stimulation of the subthalamic nuclei and mesencephalic embryonic cell grafts have shown potential in small numbers of patients. To avoid the expression of dyskinesias in already primed patients, agents that act on either the dopamine or nondopaminergic receptors have been used. For example, amantadine, given as an adjuvant to levodopa, has been shown to improve dyskinesias, but larger, controlled studies are required. SN - 0364-5134 UR - https://www.unboundmedicine.com/medline/citation/10762146/Medical_treatment_of_levodopa_induced_dyskinesias_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0364-5134&date=2000&volume=47&issue=4 Suppl 1&spage=S179 DB - PRIME DP - Unbound Medicine ER -